Last reviewed · How we verify
Reference Treatment- BMS-986165-01 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Reference Treatment- BMS-986165-01 (Reference Treatment- BMS-986165-01) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Reference Treatment- BMS-986165-01 TARGET | Reference Treatment- BMS-986165-01 | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Reference Treatment- BMS-986165-01 CI watch — RSS
- Reference Treatment- BMS-986165-01 CI watch — Atom
- Reference Treatment- BMS-986165-01 CI watch — JSON
- Reference Treatment- BMS-986165-01 alone — RSS
Cite this brief
Drug Landscape (2026). Reference Treatment- BMS-986165-01 — Competitive Intelligence Brief. https://druglandscape.com/ci/reference-treatment-bms-986165-01. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab